High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab.
Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K.
Bao H, et al. Among authors: yoshida t.
Oncol Lett. 2018 Mar;15(3):3061-3067. doi: 10.3892/ol.2017.7671. Epub 2017 Dec 20.
Oncol Lett. 2018.
PMID: 29435038
Free PMC article.